Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00209-8/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-_pK1rMKRU_vMqovSxowWmCDtJXQrdE8g1EEQfy8By2UAS8ZaQD24nx93FxrE_enTglT5nPLamtn91j1GR6_R7ZnxIiYg&_hsmi=371230603&utm_content=371146860&utm_source=hs_email Editorial p817 Politics and pharma: hurdles in UK science ambitions The Lancet Oncology +... https://www.thelancet.com/journals/lanonc/issue/vol26no7/PIIS1470-2045(25)X0007-3